Guardant Health Partners with Abu Dhabi for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, has taken a significant step in cancer screening by collaborating with the Abu Dhabi Public Health Center (ADPHC) for a new blood-based colorectal cancer screening initiative using the advanced Shield™ test. This collaboration is being facilitated by Hikma Pharmaceuticals PLC, a key player in the region's healthcare landscape.
Addressing Colorectal Cancer Challenges
Colorectal cancer is notable for being one of the leading types of cancer affecting the local population, with about 63% of cases identified at advanced stages. Such late-stage diagnoses pose serious risks, making early detection crucial for improving survival rates. The introduction of Guardant’s Shield test aims to enhance screening participation and improve early detection rates across the community.
Implementation Across Key Healthcare Facilities
This innovative screening program will be integrated into ADPHC’s IFHAS comprehensive health initiative, thereby making it available at numerous major healthcare facilities operated by Ambulatory Healthcare Services and M42, spread throughout Abu Dhabi, Al Ain, and the Al Dhafra region. The goal is to provide a more comfortable testing experience that encourages higher adherence rates — a common obstacle in detecting colorectal cancer early.
Expert Insights on the New Program
“Early detection of colorectal cancer can dramatically improve survival rates,” said AmirAli Talasaz, co-CEO of Guardant Health. He emphasized that this program aims to prioritize community health by offering a more pleasant screening alternative, ultimately leading to better health outcomes for UAE residents.
Goals for the Screening Program
The new blood-based colorectal cancer screening initiative is projected to reach approximately 10,000 individuals in its inaugural year. By broadening access to effective screening methods, Guardant Health and ADPHC are working hand-in-hand to create a healthier future for the community.
About Guardant Health
Since its founding in 2012, Guardant Health has established itself as a leader in precision oncology, dedicated to empowering individuals by extending their cancer-free times. The company is committed to transforming patient care through its innovative blood and tissue tests, real-world data, and the integration of AI analytics. Guardant's diverse range of tests enhances outcomes throughout the care spectrum—spanning cancer detection, treatment selection, and monitoring for recurrence.
Frequently Asked Questions
What is the purpose of the Guardant Shield test?
The Guardant Shield test is designed for non-invasive blood-based screening for colorectal cancer, aimed at improving early detection rates in the community.
How will the screening program improve health outcomes?
By providing a more pleasant screening experience and increasing accessibility, the program aims to boost participation and ensure early detection of colorectal cancer, significantly enhancing survival rates.
Who is involved in the collaboration for this program?
This initiative is a partnership between Guardant Health and the Abu Dhabi Public Health Center, supported by Hikma Pharmaceuticals PLC, focusing on improving cancer screening accessibility.
What are the expected screening targets?
In its first year, the program aims to screen around 10,000 individuals in regions including Abu Dhabi and Al Ain.
How did Guardant Health start?
Guardant Health was founded in 2012 with a mission to enhance cancer care through innovative testing solutions and deep insights into disease drivers.
